Market accessOfficial

SÚKL publishes draft Czech price and reimbursement list for foods for special medical purposes

🇨🇿 SÚKL · Tue 10 Nov 2026

The Czech medicines agency's draft list, dated 10 November 2026, sets out reimbursed PZLÚ products, manufacturer prices, reimbursement levels and co-payments, and is open for comment until the 20th of the month.

The State Institute for Drug Control (SÚKL) in the Czech Republic has released a draft List of Prices and Reimbursements for foods for special medical purposes (PZLÚ) as of 10 November 2026. It was published by the agency's price and reimbursement regulation section.

According to SÚKL, the list gives a complete overview of categorised and non-categorised PZLÚ reimbursed from public health insurance. For each product it shows the notified manufacturer price or the maximum manufacturer price set by the authorities, together with the reimbursement amount and conditions. It also gives the highest possible reimbursement for the end consumer and the patient co-payment that counts toward the limit. For categorised PZLÚ, the list also includes the base reimbursements for the reimbursement groups.

The draft takes account of the 12% VAT rate and of Ministry of Health Price Decision No. 1/2026/OLZP of 24 October 2025, which regulates prices of medicinal products and PZLÚ. SÚKL stresses that the document contains preliminary information only, as part of a draft.

The agency has posted the full file with current reimbursements in XLS and CSV formats, along with files showing additions and removals compared with the previous list, SCAU261101v02. It has also published check summaries of changes in reimbursements, maximum prices and countable co-payments, changes to indication restrictions, and explanatory code lists and a data interface description. Comments on the draft may be sent by email to SÚKL's SCAU address until the 20th day of the calendar month, using the subject line "Návrh Seznamu_PZLÚ".

What it means for your team

  • Market-access and reimbursement teams with PZLÚ in the Czech Republic can compare the draft against the previous list, SCAU261101v02, using the published addition and removal files.
  • The change summaries for reimbursements, maximum prices, co-payments and indication restrictions help identify products affected before the list is finalised.
  • Companies wishing to comment have until the 20th of the month and must email SÚKL with the specified subject line.
  • The item has no direct pharmacovigilance implications.

Official source: SÚKL ↗

Article written by VigiEye from the official source (SÚKL). AI-assisted; check the source before acting.

More Market access All →